Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
BG9928 in Subjects With Hepatic Impairment
- Conditions
- First Posted Date
- 2009-03-09
- Last Posted Date
- 2010-01-27
- Lead Sponsor
- Biogen
- Target Recruit Count
- 23
- Registration Number
- NCT00858156
A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS
- First Posted Date
- 2009-02-05
- Last Posted Date
- 2018-02-15
- Lead Sponsor
- Biogen
- Target Recruit Count
- 48
- Registration Number
- NCT00837785
- Locations
- 🇩🇪
Research Site, Berlin, Germany
BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
- Conditions
- Interventions
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2020-12-31
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1736
- Registration Number
- NCT00835770
- Locations
- 🇬🇧
Research Site, Stoke on Trent, United Kingdom
🇺🇸research Site, Mesa, Arizona, United States
A Phase II, Multicenter, Open-Label, Long-Term Study of the Safety, Tolerability, and Efficacy of Intravenous Natalizumab in Subjects With Rheumatoid Arthritis Who Have Previously Participated in Study ELN100226-RA201
- First Posted Date
- 2009-01-29
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- Biogen
- Registration Number
- NCT00831649
Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects
- First Posted Date
- 2009-01-23
- Last Posted Date
- 2014-06-03
- Lead Sponsor
- Biogen
- Target Recruit Count
- 95
- Registration Number
- NCT00828204
- Locations
- 🇺🇸
Fort Wayne Neurological Center, Fort Wayne, Indiana, United States
🇺🇸Research Site, Charleston, West Virginia, United States
🇺🇸Michigan Institute for Neurological Disorders, Farmington Hills, Michigan, United States
A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function
- First Posted Date
- 2009-01-07
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Biogen
- Target Recruit Count
- 30
- Registration Number
- NCT00818038
Efficacy and Safety Study of BG00012 With Methotrexate in Patients With Active Rheumatoid Arthritis
- First Posted Date
- 2008-12-18
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 153
- Registration Number
- NCT00810836
- Locations
- 🇸🇰
Research Site, Piestany, Slovakia
Study of Tysabri (Natalizumab) in Patients Who Failed Anti-TNF-α Therapy
- Conditions
- First Posted Date
- 2008-12-03
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- Biogen
- Registration Number
- NCT00801125
Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2008-12-03
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Biogen
- Target Recruit Count
- 40
- Registration Number
- NCT00801060
- Locations
- 🇺🇸
University of Florida/Pulmonary, Critical Care & Sleep Medicine, Gainesville, Florida, United States
🇺🇸Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇺🇸Vanderbilt University Medical Center-IPF Program, Nashville, Tennessee, United States
Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients
- First Posted Date
- 2008-11-04
- Last Posted Date
- 2014-05-07
- Lead Sponsor
- Biogen
- Target Recruit Count
- 3
- Registration Number
- NCT00784836
- Locations
- 🇺🇸
MS Center at Texas Neurology, Dallas, Texas, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States